trishulatx.com - TTX-030 | anti-CD39 antibody | Trishula Therapeutics

home > domains > trishulatx.com

Description: Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class anti-CD39 antibody.

Example domain paragraphs

Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.  

Our focus is on developing transformational cancer medicines by targeting the mechanisms of immune evasion in the tumor microenvironment. TTX-030, a novel, first-in-class antibody, is currently being studied in phase 1/1b clinical trials.  

Learn More

Links to trishulatx.com (2)

• mpmcapital.com Home - MPM Capital
• lightstonevc.com Lightstone Ventures – Investing in Medical Breakthroughs